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tion in uremia, although the exact pathophysiology remainsImpaired endothelial function in isolated human uremic resis-
unclear. Endothelial dysfunction may predispose the patienttance arteries.
to accelerated atherosclerosis and may be involved in theBackground. Patients with chronic renal failure (CRF) face
pathogenesis of hypertension in end-stage renal failure.a markedly increased risk of cardiovascular death. CRF is fre-
quently complicated by hypertension and changes in both the
heart (left ventricular hypertrophy) and the vasculature (endo-
thelial dysfunction and accelerated atherosclerosis). The mech- Patients with advanced renal failure no longer die ofanisms underlying changes in vascular function and specifically
uremia but are successfully treated by dialysis and renalendothelial dysfunction are unclear. This present study there-
transplantation, with constantly improving long-term re-fore examined subcutaneous resistance artery function in vitro,
comparing adult uremic patients and controls using wire myog- sults. The new threat for patients on renal replacement
raphy. therapy is premature cardiovascular death (CVD), with
Methods. Subcutaneous fat biopsies were obtained from 12 studies suggesting a 10- to 20-fold increased risk of CVDpatients with CRF (median serum creatinine 735 mol/L) at
compared with the general population [1]. The mecha-the time of renal transplantation or peritoneal dialysis catheter
nisms underlying this greatly increased risk of CVD areinsertion, and from eight controls without renal disease at the
time of abdominal surgery. Resistance arteries were mounted likely to involve changes in both the heart and the blood
on a wire myograph. Their contractile ability was tested with vessels. Uremia is known to be associated with hyperten-
high potassium depolarization, and endothelial integrity was sion and left ventricular hypertrophy (LVH) [2], whichtested by relaxation to acetylcholine. Cumulative concentration-
may predispose to sudden arrhythmic death. Changes alsoresponse curves were then constructed for norepinephrine, en-
occur in the blood vessels in uremia, including vasculardothelin-1, acetylcholine, and sodium nitroprusside (SNP).
Results. Following preconstriction with norepinephrine, ves- hypertrophy [3], calcification [4], and premature athero-
sels from uremic patients vasodilated less well to acetylcholine sclerosis [5], the clinical consequences being peripheral
compared with vessels from controls [maximum % relaxation
vascular disease, cerebrovascular disease, and ischemic77% (range 41, 97) vs. 98% (78, 100), P 0.001]. The vasodila-
heart disease [6].tion to SNP was similar [95% (63, 100) vs. 94% (71, 100), P 
0.751]. There was a trend toward increased maximum pressure The vascular endothelium plays a crucial role in the
(kPa) achieved with both norepinephrine and endothelin-1 in maintenance of blood vessel tone and in the prevention
vessels from uremic patients, and the contractions to both of of atherosclerosis [7]. Endothelial cells produce and re-
these agents were more prolonged in the uremic vessels.
lease vasoactive substances, including the vasoconstric-Conclusions. The pattern of normal vasodilation to SNP but
tors endothelin and thromboxane A2, and the vasodilatorreduced vasodilation to acetylcholine is consistent with endo-
thelial dysfunction due to impaired nitric oxide (NO) produc- substances nitric oxide (NO), endothelium-derived hyper-
tion in uremic vessels. Similar results have been demonstrated polarizing factor (EDHF), and prostacyclin. Endothelial
in vivo in uremia, one suggested mechanism being accumula- dysfunction is an early abnormality in the developmenttion of endogenous inhibitors of NO synthase such as asymmet-
of atherosclerotic plaques and is present in hyperlipid-ric dimethylarginine (ADMA). This in vitro study suggests that
emia [8], diabetes [9], hypertension [10], and cigarettea short-lived circulating factor is not entirely responsible and
that there may be an inherent abnormality in endothelial func- smokers [11]. In uremia, several in vivo studies have
also suggested endothelial dysfunction and, in particular,
a reduction in the production or effect of NO [12–14].Key words: uremia, vascular endothelium, nitric oxide, wire myog-
raphy, atherosclerosis, hypertension, ESRD. One proposed mechanism is that there is an accumulation
of endogenous inhibitors of NO synthase (NOS) such asReceived for publication October 10, 2000
asymmetric dimethylarginine (ADMA) in chronic renaland in revised form February 27, 2001
Accepted for publication March 19, 2001 failure (CRF) [15]. Our present study sought to examine
endothelial function in uremia and to determine the rele- 2001 by the International Society of Nephrology
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Table 1. Background characteristics for uremic patients and mmol/L: NaCl 118.4, KCl 4.7, MgSO4·H2O 1.2, NaHCO3controls expressed as median (range) with comparison by
24.9, CaCl2 2.5, glucose 11.1, and ethylenediaminetetra-chi-square or Mann-Whitney U tests
acetic acid (EDTA) 0.023, which gives a pH of 7.4 when
Control Uremic aerated with a 5% CO2/95% O2 mixture]. Where possi-(N  8) (N  12) P value
ble, four resistance vessels 2 mm long were dissected
Male 5 8 NS
and mounted on two 40m diameter stainless steel wiresSmoker 3 4 NS
Age years 42 (31, 73) 46 (20, 77) 0.910 in a four-channel myograph. The temperature was main-
Urea mmol/L 5.5 (2.7, 10.2) 21.8 (7.2, 35.1) 0.001 tained at 37C, and the medium was continuously aerated
Creatinine lmol/L 85 (66, 123) 735 (476, 1041) 0.001
with a 5% CO2/95% O2 mixture.Glucose mmol/L 4.7 (4.3, 6.0) 5.2 (3.4, 6.8) 0.913
Cholesterol mmol/L 4.6 (2.8, 7.4) 4.5 (3.7, 5.3) 0.408
Triglyceride mmol/L 0.9 (0.7, 3.2) 1.4 (0.8, 2.0) 0.902 Protocol
Hemoglobin g/dL 13.2 (11.8, 14.5) 9.8 (7.9, 11.1) 0.001
After a 30-minute acclimatization period, the vesselSBP mm Hg 124 (106, 152) 149 (112, 180) 0.043
DBP mm Hg 78 (68, 88) 82.5 (52, 110) 0.601 was normalized at internal diameter L0 [16]; the arteries
BMI 23.6 (16.8, 28.3) 25.2 (19.8, 30.8) 0.315 were then exposed twice to KPSS (PSS with KCl substi-
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood pres- tuted for NaCl on an equimolar basis) and once to nor-
sure; BMI, body mass index.
epinephrine 10 mol/L. After a plateau contraction had
been reached to norepinephrine, acetylcholine 3 mol/L
was added to assess endothelium-dependent vasodilation
and thus the presence of an intact endothelium. Vesselsvance of circulating inhibitors of NOS to endothelial dys-
function by studying resistance vessels removed from the that failed to contract to KPSS or norepinephrine or that
failed to relax 50% to acetylcholine were discardedcirculation. Using the in vitro technique of wire myog-
raphy, we examined the effects of endothelium-dependent (10 in the control group and 12 in the uremic group).
Two separate protocols were then carried out. A cu-(acetylcholine) and independent [sodium nitroprusside
(SNP)] vasodilators and the effects of the vasoconstric- mulative concentration-response curve to norepineph-
rine (109 mol/L to 3  104 mol/L) was constructed withtors norepinephrine and endothelin-1.
two of the vessels involving exposure to each dose of nor-
epinephrine for four minutes or until a peak response at
METHODS
that concentration was reached. Following a washout
Materials period of 30 minutes and re-establishment of baseline, a
cumulative concentration-response curve to endothelin-1Acetylcholine, SNP, and norepinephrine were pur-
chased from Sigma-Aldrich (Poole, Dorset, UK). Human (1012 mol/L to 3  106 mol/L) was constructed, with
arteries exposed to each concentration of endothelin-1endothelin-1 was purchased from ICN (Thame, UK).
Experiments were performed on a Mulvany-Halpern for 10 minutes or until a peak was reached.
With the two remaining vessels, after preconstriction4-channel myograph (JP Trading, Aarhus, Denmark).
with norepinephrine (3  106 mol/L), a concentration
Human subcutaneous resistance arteries response curve to acetylcholine (109 to 3  104 mol/L)
was constructed involving exposure to each concentra-Twelve patients with CRF agreed to have a subcutane-
ous fat biopsy at the time of continuous ambulatory tion of acetylcholine for two minutes or until the maxi-
mum relaxation was achieved. Again, following a wash-peritoneal dialysis (CAPD) catheter insertion or renal
transplantation under general anesthetic. Control tissue out period of 30 minutes, the arteries were preconstricted
with norepinephrine (3  106 mol/L), and a concentra-was obtained from volunteers without known renal dis-
ease who were undergoing abdominal surgery or hernia tion-response curve was performed for SNP (109 to 3 
104 mol/L), with arteries being in contact with eachrepair. All subjects gave written informed consent, and
the protocol was approved by the local ethics committee. concentration of SNP for two minutes or until a plateau
had been reached.The background characteristics of patients and controls
are detailed in Table 1. Subjects were excluded if they When a complete concentration-response curve was
not possible for technical reasons, the vessel was dis-had known cardiovascular disease [angina pectoris, pre-
vious myocardial infarction or coronary artery bypass carded. The number of vessels studied for each drug and
the corresponding size of these vessels are detailed ingrafting (CABG)], diabetes, or a history of vasculitis.
At the time of operation, an ellipse of skin approxi- Table 2.
mately 2  1 cm with adherent fat was removed from
Statistical analysisthe anterior abdominal wall to a depth of 2 cm. The
tissue was immediately placed into chilled 0.9% saline Contractile responses were expressed as an increase
in active effective pressure (kPa), calculated as an increaseand transported to the laboratory where it was placed
in cold physiological salt solution [PSS; composition in in isometric tension above resting divided by the normal-
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Table 2. Background data for vessels
Control Uremic P value
Norepinephrine
Number 17 22
L0 395.8 (212.2, 500.9) 360.9 (241.2, 536.4) 0.377
Endothelin-1
Number 14 16
L0 404.5 (240.2, 500.9) 374.6 (262.8, 530.5) 0.697
Acetylcholine
Number 19 23
L0 413.3 (212.2, 500.9) 345.6 (183.2, 536.4) 0.114
Sodium nitroprusside
Number 12 20
L0 358.6 (212.2, 474.4) 363.7 (183.2, 536.4) 0.833
Number is the number of vessels in which a complete concentration-response curve was obtained for that particular drug, and L0 is the normalized internal
diameter of the vessels. Comparison is by the Mann-Whitney U test.
Table 3. Potency [EC50 (molar)] of noradrenaline, endothelin-1, acetylcholine, and sodium nitroprusside in uremic and control vessels
Control Uremic P value
NA EC50 2.23107 (0.72107, 21.30107) 6.78107 (0.23107, 58.10107) 0.163
ET-1 EC50 6.011010 (0.151010, 13.501010) 9.501010 (2.691010, 71.041010) 0.208
ACh EC50 4.81108 (0.69108, 59.51108) 7.35108 (0.74108, 37.73108) 0.604
SNP EC50 5.40108 (0.58108, 87.12108) 5.43108 (0.40108, 19.05108) 0.716
Ach max % relaxation 98 (78, 100) 77 (41, 97) 0.001
SNP max % relaxation 94 (71, 100) 95 (63, 100) 0.751
Data are expressed as median (range) with comparison by Mann-Whitney U test. Abbreviations are: NA, norepinephrine; ET-1, endothelin-1; ACh, acetylcholine;
SNP, sodium nitroprusside. Maximum % relaxation from baseline of acetylcholine and sodium nitroprusside is expressed as median (range).
Fig. 2. Concentration-response curves for endothelin-1 in uremic ()Fig. 1. Concentration-response curves for norepinephrine in uremic
and control () groups. Data are mean  SEM; *P  0.01.() and control () groups. Data are mean  SEM; *P  0.001.
ized internal radius. Agonist potency was expressed in smoking habits (Table 1). Hemoglobin was significantly
terms of maximum response obtained, and EC50 value, lower in the uremic patients, and systolic blood pressure
this being the concentration required to produce 50% was significantly higher, as expected. Table 2 details the
of the maximum response. For SNP and acetylcholine, number and size of the vessels used for each drug. There
the response was expressed as maximum % relaxation was no significant difference in vessel size between groups.
from baseline. A comparison between groups was by The results for the vasoconstrictors norepinephrine
Mann-Whitney U test. All analyses were performed us- and endothelin-1 are shown in Table 3 and in Figures 1
ing SPSS for Windows (version 7.5), with significance at and 2. The potency of norepinephrine and endothelin-1
a level of P  0.05. were similar in uremic and control groups (no significant
difference in EC50). However, from the concentration
RESULTS response curves, it can be seen that there was a tendency
for a more sustained contraction to these agents withPatients and controls were of a similar age and sex
distribution and had similar total serum cholesterols and the response (kPa) at the highest dose of norepinephrine
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Fig. 3. Concentration-response curves for sodium nitroprusside in ure- Fig. 4. Concentration-response curves for acetylcholine in uremic ()mic () and control () groups. Data are mean  SEM. and control () groups. Data are mean  SEM; *P  0.001.
being significantly greater in the uremic group [16.89 study, systolic blood pressure (but not diastolic) was
higher in uremic subjects compared with controls.(1.7, 30.6) uremic vs. 6.96 (0, 25.9) control, P  0.001]
and the response to the highest dose of endothelin-1 As chronic renal failure is associated with accelerated
atherosclerosis, many have proposed that there is likelybeing significantly greater in the uremic group [19.08
to be a circulating “uremic factor” responsible for these(8.9, 37.8) uremic vs. 13.44 (2.2, 22.2) control, P 0.006].
changes. The vascular endothelium would seem a reason-The results for the endothelium-independent vasodila-
able target for such a uremic factor. Cell culture studiestor SNP are detailed in Table 3 and Figure 3. Again, the
have suggested that uremic serum may inhibit NO synthasepotency of this agent was similar in uremic and control
(iNOS) [19] and that uremic serum adversely affectsgroups, and the same maximum relaxation was obtained
endothelial extracellular matrix production and attach-in the two groups. However, when the results were exam-
ment of endothelial cells to the subendothelium [20]. Non-ined for the endothelium-dependent vasodilator acetyl-
invasive studies using Doppler ultrasound measurementcholine (Table 3 and Fig. 4), the maximum relaxation
of radial or brachial artery diameter or dorsal hand veinobtained in uremic patients (77%, range 41, 97) was
diameter have revealed impaired endothelium-depen-significantly lower than that obtained in controls (98%,
dent vasodilation in adult hemodialysis patients [12] andrange 78, 100, P  0.001).
in uremic children not yet requiring dialysis [13]. We have
also shown in adult patients with CRF that endothelium-
DISCUSSION dependent vasodilation was attenuated when studied us-
The healthy vascular endothelium acts to prevent the ing forearm plethysmography [14].
development of atherosclerosis principally through the In this present study, using an in vitro technique, we
have again demonstrated impaired endothelium-depen-production and release of NO. NO is produced continu-
ously under resting conditions from l-arginine and con- dent vasodilation and preserved endothelium-independent
vasodilation in uremia. Thus, there is general agreementtributes to basal vessel tone. NO, in addition to vasodilat-
ing, inhibits platelet aggregation, inhibits vascular smooth that uremic individuals have endothelial dysfunction, but
the exact mechanisms involved are unclear. While it ismuscle proliferation, and inhibits monocyte adhesion
and migration. Dysfunction of the vascular endothelium is possible that endothelial dysfunction simply reflects the
synergistic effect of multiple “traditional” cardiovascularlikely to manifest in several ways, but the most commonly
studied defect is a reduction in endothelium-dependent risk factors, the magnitude of the increased risk in ure-
mics over diabetics (who also have several risk factorsvasodilation, mainly as a result of reduced NO produc-
tion and/or release. Such a defect has been demonstrated for CVD) suggests that there may indeed be a “uremic
factor(s).”in several conditions, including hypercholesterolemia [8],
diabetes mellitus [9], and in cigarette smokers [11]. In Potential candidates for an atherogenic “uremic fac-
tor” include homocysteine [21], increased oxidative stressour study, subjects and controls were matched as closely
as possible for these variables. In hypertension, most stud- [22], and endogenous inhibitors of NO synthase such
as ADMA and NG-monomethyl-L-arginine (L-NMMA)ies suggest impaired endothelium-dependent vasodilation
[10, 17], although Cockcroft et al [18] found that endo- [15], two naturally occurring substances that accumulate
in renal failure because of reduced excretion and/or me-thelium-dependent vasodilation was preserved. In our
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tabolism. An eightfold rise in plasma ADMA concentra- statins [8], angiotensin-converting enzyme inhibitors [27],
tions has been reported in uremic patients compared vitamin C [28], folic acid [29], and vitamin E [30], are
with healthy controls [15], with levels approaching those already known to improve endothelial function in other
required to raise blood pressure in experimental animals. groups. Whether similar therapeutic measures will also
Other groups have subsequently demonstrated smaller improve endothelial function in uremic patients and re-
increases in ADMA concentrations in CRF [23, 24], and duce the excessive cardiovascular morbidity of this group
it remains to be seen whether the levels reached are has yet to be determined.
physiologically significant.
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